p53/E2F7轴在多形质母细胞瘤中促进了temozolomide的化学抵抗
Jiao Meng1,2, Wei Qian1,2,3, Zhenkun Yang1,2
1Department of Laboratory Medicine, Wuxi People's Hospital, Wuxi Medical Center, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Nanjing Medical University, 214023, Wuxi, Jiangsu, China.
BMC cancer
|March 8, 2024
概括
由p53驱动的高E2F7表达,通过限制药物吸收和DNA损伤,导致多种质母细胞瘤 (GBM) 化学抵抗. 这揭示了p53激活和GBM治疗失败之间的联系.
科学领域:
- 神经瘤学神经瘤学
- 癌症生物学 癌症生物学
- 癌症的分子机制 癌症的分子机制
背景情况:
- 多形质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑癌.
- 耐化学反应是治疗GBM的一个主要挑战,其潜在机制尚未完全理解.
研究的目的:
- 阐明GBM中特莫佐洛米德 (TMZ) 耐药性的机制.
- 调查E2F7在GBM化学抵抗中的作用.
主要方法:
- 生物信息学和基于抗体的蛋白质检测以分析质瘤中的E2F7表达.
- 在体外测试 (IC50,活力,殖民地形成,亡) 和体内内移植模型,以评估TMZ耐药性中的E2F7功能.
- 西方斑点和ChIP实验证实了E2F7.7的p53调节.
主要成果:
- 在GBM组织中E2F7水平升高与患者预后不佳相关.
- 在耐TMZ (TMZ-R) GBM中,E2F7被上调,这与药物摄入量减少和DNA损伤有关.
- 确定p53激活是E2F7表达的调节者.
结论:
- 通过p53调节的高E2F7表达,通过损害药物吸收和DNA损伤,为GBM赋予TMZ耐药性.
- 持续的p53激活与GBM化学抵抗有显著的联系.
- 这些发现表明了针对p53-E2F7轴的新型治疗策略,以克服GBM化学抵抗.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Negative Regulator Molecules
35.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.4K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K


